Castle Biosciences, Inc.
CSTL
$38.63
$0.661.74%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -301.42% | -205.45% | 83.54% | 131.75% | 108.05% |
| Total Depreciation and Amortization | 68.45% | 224.68% | 231.98% | 29.74% | 12.61% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.62% | -9.85% | -1.68% | -3.01% | 8.51% |
| Change in Net Operating Assets | 119.13% | 24.19% | -14.01% | -113.05% | 22.49% |
| Cash from Operations | 4.56% | 53.30% | 405.97% | 1,252.97% | 295.57% |
| Capital Expenditure | -48.27% | -35.48% | -23.05% | -107.96% | -111.38% |
| Sale of Property, Plant, and Equipment | 235.71% | 166.67% | 69.23% | 38.46% | -92.86% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 78.63% | 65.19% | 12.32% | -747.73% | -2,380.37% |
| Cash from Investing | 0.24% | -2.27% | -0.76% | -209.81% | -389.33% |
| Total Debt Issued | -100.00% | -100.00% | -100.00% | -- | -- |
| Total Debt Repaid | -6.54% | 10.08% | 39.16% | 31.69% | 23.57% |
| Issuance of Common Stock | -40.07% | 60.35% | 58.17% | 67.83% | 54.54% |
| Repurchase of Common Stock | -66.74% | -100.50% | -104.06% | -70.67% | -139.36% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -194.27% | -180.70% | -179.52% | 367.15% | 3,204.02% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -351.69% | 67.59% | 121.15% | 186.56% | 108.70% |